Fresenius Kabi
News
August 2, 2022
Fresenius Kabi’s Biologics License Application for Biosimilar Candidate Tocilizumab Accepted for Review by the FDA
read moreAugust 1, 2022
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals market
read moreJuly 27, 2022
A biosimilar patient story: "I can live my life again and not feel fear"
read moreMay 23, 2022
EuroPN Study: New clinical data on medical nutrition therapy in critically ill patients
read moreApril 30, 2022
Fresenius Kabi SwissBioSim spreads smiles and happiness with a fundraising campaign
read moreApril 29, 2022
Fresenius Kabi Biosimilars team planted trees in Switzerland
read moreMarch 31, 2022
Next generation patient care: Fresenius Kabi buys a majority stake in mAbxience and acquires Ivenix
read moreMarch 30, 2022
Fresenius Kabi receives European Commission approval for its pegfilgrastim biosimilar Stimufend®
read moreOctober 19, 2021
Fresenius Kabi wins Fierce Pharma Award 2021
read moreSeptember 7, 2021
Fresenius Kabi’s tocilizumab biosimilar candidate MSB11456 shows positive results in two clinical trials
read more
- August 9 - 11, 2022
- |
- USA, Bally’s Las Vegas
NPPA
National Pharmacy Purchasing Association
- September 7 - 11, 2022
- |
- Italy, Milan
EADV
European Academy of Dermatology and Venereology
- September 9 - 13, 2022
- |
- France, Paris
ESMO
European Society for Medical Oncology
- October 8 - 11, 2022
- |
- Austria, Vienna
UEG Week
United European Gastroenterology
